— Know what they know.
/
Not Investment Advice

HSIC

NASDAQ · USD
Henry Schein, Inc.
Healthcare · Medical - Distribution
CEO Frederick Lowery Employees 25,000 R&D / revenue 0.0%
Last price
$86.38−0.70%last session
Market cap
$9.6B
P/E (TTM)
25.0x
From 52w high
−6.3%
From 52w low
+39.2%
1-year return
+39.3%
RSI 14 · vs SMA200
52.6 · +7.1%
IS score
51.3/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

HSIC   SPY   XLV (sector ETF) · weekly closes
100110120130140150Jan 26Apr 26Jul 26Oct 26HSIC 139XLV 124SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
29
Profitability
47
Growth
44
Value
76
Momentum
65
Risk (safety)
65
Quality
37
Balance sheet
82
Earnings quality

Flags

Strengths
✓ FCF yield 5%+✓ Insider buying
Warnings
None of the computed warning flags fires for HSIC (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: None, Efficient ScalePiotroski 7 / 9Altman Z 2.8Beta 0.813 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
1
$0.69M bought
Form 144 notices (12m): 10, $16.1M proposed, not confirmed sales
CONGSTOCK Act · 180 days
Congressional purchases
0
No disclosed purchases
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
+5
71 new holders, 61 closed
569 filers hold 109.2% · 176 added, 221 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+23
491 funds adding shares
468 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
57.0%
20-day avg 59.7%, 50-day avg 66.0%
Latest 2.7 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$13.2B
Revenue growth YoY+4.0%
Gross margin29.1%
Operating income$758.0M
Operating margin5.7%
Net income$398.0M
Net margin3.0%
EPS (diluted)$3.27
Cash flow
Operating cash flow$712.0M
Capital expenditure$139.0M
Free cash flow$573.0M
FCF conversion (FCF / OCF)80.5%
Stock-based compensation$0
FCF less SBC$573.0M
Buybacks$850.0M
Dividends$0
Balance sheet & returns
Cash & short-term investments$156.0M
Total debt$3.4B
Net debt$3.3B
Shareholders' equity$4.8B
Goodwill & intangibles$5.2B
Debt / equity1.21
ROE (TTM)12.4%
ROIC (TTM)6.5%
Operating margin by fiscal year
6.9%FY20216.9%FY20225.6%FY20235.8%FY20245.8%FY2025
Revenue $12.4B (FY2021) to $13.2B (FY2025), a 1.5% CAGR.

Valuation

P/E (TTM)25.0x
EV / EBITDA12.7x
Price / sales0.71x
Price / FCF17.9x
FCF yield5.60%
Buyback yield8.83%
SBC / revenue0.2%
Price / book3.10x
Forward P/E FY202616.0x
Forward P/E FY202616.3x
Forward P/E FY202714.4x
Forward multiples divide today's price by Street EPS estimates. Street mean target $97.71 across 7 analysts last quarter is theirs, not ours.

HSIC vs industry median

42 companies in Medical - Distribution
Gross margin 30.3% 9.4% Operating margin 5.7% 0.7% Net margin 3.0% 0.2% ROIC 6.5% 6.7%
HSIC (TTM)Industry median Asset turnover 1.20 vs industry 1.91 · financial leverage 3.61

Earnings delivery

Next report 2026-11-03 · consensus EPS $1.36
67%
beat rate, 8 of 12 quarters
+2.7%
median EPS surprise
4
longest beat streak
+0-6+8+1+5-3+4-7+9+3+10+2
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-11-13 to 2026-08-04. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
HSIC Henry Schein, Inc. $9.6B25.0x12.4%3.0%+4.0% +39.3%
ABC AmerisourceBergen Corporatio $36.1B13.3x103.9%0.9%+2.9% —
CAH Cardinal Health, Inc. $58.8B34.9x-60.5%0.6%+14.2% +67.3%
GKOS Glaukos Corporation $9.7Bn/m-26.0%-9.9%+41.5% +93.2%
IBRX ImmunityBio, Inc. $9.7Bn/m122.7%—+192.9% +262.8%
QGEN Qiagen N.V. $9.5B23.7x11.9%19.3%+3.0% −4.2%
PODD Insulet Corp. $9.8B26.3x26.0%11.8%+29.4% —
BIO Bio-Rad Laboratories, Inc. $9.5B42.5x3.1%57.1%+1.4% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-10-08Officer/Director Change; Regulation FD; Exhibits
2026-09-22Material Agreement; Financial Obligation; Exhibits
2026-08-04Earnings Release; Exhibits
2026-07-30Officer/Director Change; Regulation FD; Exhibits
2026-05-22Shareholder Vote; Regulation FD; Exhibits
2026-05-05Earnings Release; Exhibits

Context

Shares outstanding111,447,000
Free float82.3%
Institutional ownership109.2%
Beta0.81
Dividend yield0.00%
Last dividendNone on file
50 / 200-day average$87.42 / $80.62
Mid-cap Healthcare median P/E27.1x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (None).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where HSIC sits among 5 scored companies in Medical - Distribution (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasureHSICIndustry medianIndustry percentileSector median
P/E (TTM) 23.9x — 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) —
Price / sales 0.7x 0.3x
75th		 3.7x
Price / book 3.0x — 3.6x
Price / tangible book —
Price / free cash flow 17.9x — 21.2x
Price / operating cash flow 13.8x — 17.1x
Enterprise value $13.3B $63.9B
25th		 $2.5B
EV / sales 1.0x 0.3x
75th		 3.8x
EV / EBITDA 12.9x — 16.2x
EV / EBIT 18.5x — 23.0x
EV / free cash flow 24.6x — 24.6x
Earnings yield 4.2% 3.9%
100th		 -0.3%
FCF yield 5.6% 5.6%
50th		 1.7%
Operating cash flow yield 7.3% 7.3%
50th		 2.9%
Graham number (per share) $46.77 — $26.70

Profitability (TTM)

MeasureHSICIndustry medianIndustry percentileSector median
Gross margin 30.3% 3.7%
100th		 65.1%
EBITDA margin 7.6% 1.5%
100th		 6.6%
Operating margin 5.7% 1.3%
100th		 3.5%
EBIT margin 5.3% 1.2%
100th		 2.4%
Net margin 3.0% 0.8%
100th		 0.3%
NOPAT margin 4.3% 1.0%
100th		 2.7%
FCF margin 4.0% 1.5%
100th		 4.3%
Operating cash flow margin 5.1% 1.7%
100th		 7.1%
R&D / revenue 0.0% 0.0%
0th		 12.4%
SG&A / revenue 23.5% 2.4%
75th		 37.9%
Stock comp / revenue 0.2% 0.0%
100th		 4.5%
Effective tax rate 23.7% 21.6%
75th		 21.0%

Returns on capital

MeasureHSICIndustry medianIndustry percentileSector median
ROE (on average equity) 12.2% — 0.8%
ROA 3.6% 3.3%
75th		 -0.3%
ROIC 8.7% 26.5%
25th		 5.5%
ROCE 9.1% 16.6%
25th		 2.3%
Return on tangible assets 6.4% 5.2%
75th		 1.7%
Cash ROIC (OCF / invested capital) 10.3% 40.3%
25th		 9.7%
Gross profitability (GP / assets) 36.2% 16.9%
100th		 29.9%
ROIC, 3-yr average 6.4% — 2.6%
ROIC, 5-yr average 9.3% — 3.2%
ROE, 5-yr average 13.0% — -4.9%
Incremental ROIC 176.0% 127.4%
100th		 17.2%

Growth

MeasureHSICIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) 6.5% 8.8%
25th		 10.5%
Revenue growth (QoQ) 2.7% 4.8%
25th		 7.2%
Revenue CAGR, 3 yr 2.6% 7.4%
25th		 10.7%
Revenue CAGR, 5 yr 2.7% 10.2%
0th		 12.1%
Gross profit CAGR, 3 yr 3.9% — 10.6%
Operating income CAGR, 3 yr -2.6% — 11.7%
Net income growth (TTM YoY) 3.6% — 17.5%
Net income CAGR, 3 yr -4.2% — 11.3%
EPS growth (TTM YoY) 11.1% — 19.2%
EPS CAGR, 3 yr 0.5% — 14.0%
EPS CAGR, 5 yr -3.8% — 8.1%
FCF growth (TTM YoY) 50.6% — 18.6%
FCF CAGR, 3 yr 0.4% — 15.4%
Operating cash flow CAGR, 3 yr 2.3% — 11.9%
Book value CAGR, 3 yr 0.7% — 2.1%
Dividend CAGR, 3 yr —
Sustainable growth rate 12.2% — 12.2%

Margin history & stability

MeasureHSICIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 29.8% 3.6%
100th		 62.6%
Operating margin, 3-yr average 5.5% 1.1%
100th		 1.0%
Net margin, 3-yr average 2.9% 0.7%
100th		 -2.6%
FCF margin, 3-yr average 3.6% 1.3%
100th		 3.2%
Revenue stability (0-1) 0.85 0.94
25th		 0.80
Earnings stability (0-1) 0.69 0.57
100th		 0.37
Margin stability (0-1) 0.98 0.90
100th		 0.93

Liquidity (latest quarter)

MeasureHSICIndustry medianIndustry percentileSector median
Cash & short-term investments $157.0M $2.8B
25th		 $330.9M
Net cash (− = net debt) −$3.7B −$5.1B
75th		 $8.4M
Working capital $1.1B −$3.9B
100th		 $381.1M
Current ratio 1.32 0.93
75th		 3.02
Quick ratio 0.73 0.58
75th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.05 0.05
25th		 1.43
Defensive interval (days) 209 days 952 days
25th		 415 days

Leverage & solvency (latest quarter)

MeasureHSICIndustry medianIndustry percentileSector median
Total debt $3.8B $9.9B
25th		 $289.1M
Debt / equity 1.21 — 0.45
Net debt / equity 1.16 — −0.13
Debt / assets 33.5% 14.0%
100th		 24.4%
Debt / capital 54.7% — 31.1%
Debt / EBITDA 3.70 — 2.62
Net debt / EBITDA 3.55 — 1.42
Interest coverage (EBIT / interest) 4.5x — 2.1x
Cash interest coverage 4.4x — 3.6x
Debt payback (years of OCF) 5.4 yrs — 2.7 yrs
Liabilities / assets 58.5% 96.1%
25th		 49.8%
IS credit model rating BBB — —
Implied credit spread (bps) 275 125
75th		 225

Efficiency

MeasureHSICIndustry medianIndustry percentileSector median
Asset turnover 1.22 4.22
25th		 0.56
Fixed asset turnover 14.47 88.86
0th		 4.87
Inventory turnover 4.8 15.4
0th		 2.7
Receivables turnover 8.0 13.3
0th		 6.4
Days sales outstanding 46 days 27 days
100th		 57 days
Days inventory outstanding 76 days 24 days
100th		 136 days
Days payables outstanding 40 days 54 days
25th		 59 days
Cash conversion cycle (days) 83 days −6 days
100th		 70 days
Capex / revenue 1.2% 0.2%
100th		 2.6%
Capex / depreciation 0.51 0.68
25th		 0.55
Operating expense ratio 26.1% 3.2%
75th		 56.5%

Cash flow & earnings quality

MeasureHSICIndustry medianIndustry percentileSector median
Operating cash flow / net income 1.74 — 1.61
FCF / net income 1.34 — 1.36
FCF / operating cash flow 77.0% — 81.2%
Capex / operating cash flow 23.0% — 18.8%
Accruals ratio -2.7% -2.8%
100th		 -5.4%
Sloan accruals ratio -3.9% -2.1%
25th		 -1.3%
Earnings quality score (0-1) 1.00 — 0.75

Dividends & buybacks

MeasureHSICIndustry medianIndustry percentileSector median
Dividend yield 0.0% 0.3%
0th		 0.0%
Dividend per share (TTM) $0.00 $2.05
0th		 $0.00
Payout ratio (dividends / net income) 0.0% — 0.0%
Dividends / FCF 0.0% — 0.0%
Dividend growth (YoY) —
Buyback yield 7.6% 2.3%
100th		 0.0%
Shareholder yield (dividends + buybacks) 7.6% 3.1%
100th		 0.0%
Share count change (YoY) -6.7% -1.2%
0th		 2.0%
Buybacks, last 5 years $1.8B $2.0B
25th		 $0

Scores & forensic checks

MeasureHSICIndustry medianIndustry percentileSector median
IS score 51 59
25th		 46
IS profitability 29 8
100th		 22
IS growth 47 68
0th		 60
IS value 44 44
50th		 39
IS momentum 76 84
25th		 67
IS risk (safety) 65 100
0th		 80
IS quality 65 57
100th		 49
IS balance sheet 37 42
0th		 55
IS earnings quality 82 82
25th		 56
IS cash flow 61 61
50th		 41
Piotroski F-score (0-9) 7 7
25th		 5
Altman Z-score 2.8 5.1
0th		 3.2
Beneish M-score −2.58 −2.69
75th		 −2.62
Ohlson O-score −7.58 −6.84
0th		 −7.16
IS credit score 57 76
25th		 62

Per share

MeasureHSICIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $3.52 $7.23
25th		 −$0.03
Book value per share $27.60 $0.25
100th		 $7.10
Tangible book per share −$4.53 −$69.30
75th		 $1.91
Revenue per share $118.91 $1,072.78
25th		 $9.38
FCF per share $4.71 $19.09
25th		 $0.46
Operating cash flow per share $6.12 $21.83
25th		 $0.93
Cash per share $1.37 $14.52
25th		 $3.51

Size (TTM)

MeasureHSICIndustry medianIndustry percentileSector median
Market cap $9.6B $58.8B
25th		 $2.4B
Revenue $13.6B $254.2B
25th		 $770.2M
EBITDA $1.0B $3.5B
25th		 $56.1M
Net income $403.0M $1.7B
25th		 −$3.3M
Free cash flow $539.0M $4.1B
25th		 $41.2M
Total assets $11.4B $57.3B
25th		 $1.3B
Shareholders' equity $3.2B $180.9M
100th		 $568.4M
Employees 25,000 42,300
25th		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-09-08Albertini Andrea
CEO, Global Dist. & Tech.
 Tax withholding 603$88.86$53,583120,088
2026-09-08Albertini Andrea
CEO, Global Dist. & Tech.
 Return to issuer 3,984——116,104
2026-06-12Daniel William K
Director
 Award / grant 2,215——7,641
2026-05-26Bergman Stanley M
other: Former Director
 Gift 50——253,279
2026-05-21Murphy Kelly Ann
SVP & General Counsel
 — 1,479$62.71$92,7480
2026-05-21Murphy Kelly Ann
SVP & General Counsel
 — 9,274$76.76$711,8720
2026-05-21Murphy Kelly Ann
SVP & General Counsel
 — 2,979$86.27$256,9980
2026-05-21Bergman Stanley M
Director
 Gift 50——253,279
2026-05-19Bergman Stanley M
Director
 Gift 1,040——253,329
2026-05-11Daniel William K
Director
 Open-market buy 10,000$69.19$691,90020,000

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarMayJunSep

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired12,215—
GiftDisposed31,140—
Open-market buyAcquired110,000$691,900
Return to issuerDisposed13,984—
Tax withholdingDisposed1603$53,583
—Disposed413,732$1.1M
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

12 months: 10 notices · 192,924 shares · $16.1M
FiledFilerShares proposedEst. proceeds
2026-08-14Stanley M. Bergman35,257$3.2M
2026-06-30Herring Joseph L28,791$2.4M
2026-06-16Stanley M. Bergman16,933$1.4M
2026-03-19Popeck Thomas C1,355$98,630
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 4 trades (0 purchases) · Senate 0 (0 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-06-18Michael McCaulHouseSale$1,001 - $15,0002026-07-13
2026-06-18Michael T. McCaulHouseSale$1,001 - $15,0002026-07-13
2026-01-09Michael McCaulHouseSale$15,001 - $50,0002026-02-12
2026-01-09Michael T. McCaulHouseSale$15,001 - $50,0002026-02-12
2022-01-06Susan M. CollinsSenateSale (Full)$15,001 - $50,0002022-02-17
2022-01-06Susan M. CollinsSenateSale (Full)$15,001 - $50,0002022-02-16
2022-01-06Susan Margaret CollinsSenateSale (Full)$15,001 - $50,0002022-02-16
2014-11-10Susan M. CollinsSenatePurchase$1,001 - $15,0002014-12-01
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
Kohlberg Kravis Roberts & Co. L.P.15,652,032$1.3B14.04%
FMR LLC7,553,901$630.9M6.78%
BlackRock, Inc.7,024,663$586.7M6.30%
Artisan Partners Limited Partnership6,467,467$540.2M5.80%
VANGUARD CAPITAL MANAGEMENT LLC6,346,669$530.1M5.69%
STATE STREET CORP4,305,276$359.6M3.86%
JPMORGAN CHASE & CO4,298,367$362.7M3.86%
VANGUARD PORTFOLIO MANAGEMENT LLC4,133,442$345.2M3.71%
AMERICAN CENTURY COMPANIES INC3,457,175$288.7M3.10%
DIMENSIONAL FUND ADVISORS LP3,394,242$283.5M3.05%
Invesco Ltd.3,150,237$263.1M2.83%
CITADEL ADVISORS LLC2,921,103$244.0M2.62%
GEODE CAPITAL MANAGEMENT, LLC2,729,030$227.5M2.45%
BANK OF MONTREAL /CAN/2,115,510$176.7M1.90%
FIDUCIARY MANAGEMENT INC /WI/1,817,353$151.8M1.63%

Institutional ownership by quarter

2023-092026-06109.2%
% of shares held by 13F filers
2023-092026-06569
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-30569109.2%7117622161
2026-03-31564106.1%7518119545
2025-12-31546106.7%7414723664
2025-09-30550112.2%6515223070
2025-06-30562119.5%7718622370
2025-03-31560112.8%9416221571
2024-12-31544112.9%7417620949
2024-09-30530114.5%5416722874
2024-06-30556111.1%6718621151
2024-03-31544111.3%4816622560
2023-12-31565111.2%7218621952
2023-09-30556108.2%5617523352

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-04-30SCHEDULE 13GVanguard Capital Management6.4%7,302,660
2026-03-27SCHEDULE 13G/AThe Vanguard Group0.0%0
2026-03-10SCHEDULE 13D/AKKR Hawaii Aggregator L.P.16.1%18,464,701
2026-03-10SCHEDULE 13D/AGeorge R. Roberts16.4%18,853,071
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.01%$253.2M
VTSAX0.01%$253.2M
VSMPX0.01%$253.2M
VTI0.01%$253.2M
VFFSX0.01%$211.2M
VOO0.01%$211.2M

Share structure

Shares outstanding111,447,000
Float91,710,474
Free float82.3%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$12.4B$12.6B$12.3B$12.7B$13.2B
Cost of revenue$8.7B$9.0B$8.7B$8.9B$9.3B
Gross profit$3.7B$3.6B$3.7B$3.8B$3.8B
R&D$0$0$0$0$0
SG&A$2.8B$2.7B$2.9B$3.0B$3.1B
Operating income$854.8M$938.0M$714.0M$729.0M$758.0M
EBITDA$1.1B$977.0M$877.0M$941.0M$1.0B
Pretax income$850.6M$736.0M$556.0M$526.0M$545.0M
Income tax$197.3M$170.0M$120.0M$128.0M$126.0M
Net income$623.9M$538.0M$416.0M$390.0M$398.0M
EPS, diluted$4.45$3.91$3.16$3.05$3.27
Diluted shares141.8M137.8M131.7M127.8M121.7M

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$118.0M$117.0M$171.0M$122.0M$156.0M
Receivables$1.5B$1.4B$1.9B$1.5B$1.7B
Inventory$1.9B$2.0B$1.8B$1.8B$2.0B
Total current assets$3.8B$4.0B$4.5B$4.0B$4.5B
PP&E, net$691.0M$667.0M$823.0M$824.0M$922.0M
Goodwill & intangibles$3.5B$3.5B$4.8B$4.9B$5.2B
Total assets$8.5B$8.6B$10.6B$10.2B$11.2B
Accounts payable$1.1B$1.0B$1.0B$962.0M$1.2B
Total current liabilities$2.3B$2.2B$2.7B$2.8B$3.2B
Long-term debt$811.0M$1.0B$1.9B$1.8B$2.6B
Total liabilities$3.8B$3.9B$5.4B$5.4B$6.4B
Shareholders' equity$4.7B$4.7B$5.2B$4.8B$4.8B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$660.5M$566.0M$416.0M$398.0M$398.0M
Depreciation & amortization$209.5M$212.0M$222.0M$268.0M$311.0M
Stock-based compensation$78.0M$54.0M$39.0M$39.0M$0
Change in working capital−$197.2M−$281.0M−$234.0M$140.0M−$48.0M
Operating cash flow$709.6M$602.0M$500.0M$848.0M$712.0M
Capital expenditure−$79.0M−$96.0M−$147.0M−$187.0M−$139.0M
Free cash flow$630.6M$506.0M$353.0M$661.0M$573.0M
Investing cash flow−$677.2M−$276.0M−$1.1B−$430.0M−$477.0M
Net debt issued / repaid$165.0M$259.0M$900.0M$189.0M$551.0M
Buybacks−$401.0M−$485.0M−$284.0M−$385.0M−$850.0M
Dividends paid$0$0$0$0$0

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin29.6%28.9%29.6%29.7%29.1%
Operating margin6.9%6.9%5.6%5.8%5.8%
Net margin5.0%4.3%3.4%3.1%3.0%
FCF margin5.1%4.0%2.9%5.3%4.3%
ROE18.4%15.7%11.7%11.1%12.0%
ROIC14.6%14.0%8.8%9.0%8.7%
ROA7.7%6.3%4.3%3.8%3.7%
Debt / equity0.360.430.750.851.14
Interest coverage31.1x17.4x7.2x4.9x4.6x
Current ratio1.671.791.671.421.38
Revenue growth+22.6%+2.0%−2.4%+2.7%+4.0%
EPS growth+58.4%−10.9%−19.7%−2.4%+8.3%
P/E at year end17.4x20.2x23.8x22.3x22.6x
EV / EBITDA at year end11.2x12.5x14.2x12.2x12.6x
FCF yield at year end5.80%4.66%3.57%7.72%6.23%
Dividend payout0.0%0.0%0.0%0.0%0.0%

Street estimates by fiscal year

Next report 2026-11-03 · consensus EPS $1.36 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$13.9B$13.8B – $13.9B$5.39$5.35 – $5.431016.0x
2026$13.6B$13.5B – $13.7B$5.30$5.23 – $5.371116.3x
2027$14.4B$14.3B – $14.6B$5.99$5.87 – $6.271114.4x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-08-04$1.24$1.27+2.4%$3.4B$3.5B+2.5%
2026-05-05$1.20$1.32+10.0%$3.3B$3.4B+0.8%
2026-02-24$1.30$1.34+3.1%$3.3B$3.4B+2.7%
2025-11-04$1.27$1.38+8.7%$3.3B$3.3B−0.2%
2025-08-05$1.18$1.10−6.8%$3.3B$3.2B−1.1%
2025-05-05$1.11$1.15+3.6%$3.2B$3.2B−1.5%
2025-02-25$1.23$1.19−3.3%$3.3B$3.2B−3.1%
2024-11-05$1.16$1.22+5.2%$3.4B$3.2B−5.6%
2024-08-06$1.22$1.23+0.8%$3.3B$3.1B−4.4%
2024-05-07$1.02$1.10+7.8%$3.2B$3.2B−1.0%
2024-02-27$0.70$0.66−5.7%$3.0B$3.0B−0.6%
2023-11-13$1.32$1.320.0%$3.2B$3.2B−1.8%
2023-08-07$1.28$1.31+2.3%$3.1B$3.1B−0.8%
2023-05-09$1.24$1.21−2.4%$3.1B$3.1B−1.0%
2023-02-16$1.21$1.210.0%$3.4B$3.4B+0.5%
2022-11-01$1.14$1.09−4.4%$3.2B$3.1B−3.9%
2022-08-02$1.16$1.160.0%$3.1B$3.0B−2.9%
2022-05-03$1.19$1.30+9.2%$3.1B$3.2B+2.5%
2022-02-15$0.91$1.07+17.6%$3.2B$3.3B+5.6%
2021-11-02$0.95$1.10+15.8%$2.9B$3.2B+8.5%
2021-08-03$0.97$1.11+14.4%$2.9B$3.0B+3.3%
2021-05-04$0.84$1.24+47.6%$2.8B$2.9B+4.2%
2021-02-17$0.99$1.00+1.0%$2.9B$3.2B+10.2%
2020-11-02$0.79$1.03+30.4%$2.2B$2.8B+30.4%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.106-150.106-220.106-290.207-060.207-130.107-200.207-270.308-030.108-100.108-170.108-240.108-31
Week ofNotionalSharesTrades
2026-08-31$100.1M1,111,46234,260
2026-08-24$111.5M1,238,96330,326
2026-08-17$115.2M1,288,92639,901
2026-08-10$124.3M1,386,84338,576
2026-08-03$289.2M3,268,94672,289
2026-07-27$185.5M2,168,60548,288

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1557.0%
DateShort shareShort volumeTotal volume
2026-10-1557.0%209,291367,395
2026-10-1467.5%256,676380,382
2026-10-1377.9%234,749301,504
2026-10-1267.9%233,807344,568
2026-10-0967.5%271,108401,676
2026-10-0875.9%807,7981,064,439
2026-10-0768.8%395,084573,862
2026-10-0664.7%349,591540,273
2026-10-0568.3%539,787790,381
2026-10-0270.6%296,521420,051
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
+2.5Jan+0.3Feb+0.9Mar+0.2Apr+1.7May+0.3Jun+1.8Jul-1.6Aug-0.5Sep-0.8Oct+2.1Nov+0.8Dec
MonthAvg returnUp yearsYears
Jan+2.5%65%20
Feb+0.3%65%20
Mar+0.9%67%21
Apr+0.2%45%20
May+1.7%65%20
Jun+0.3%40%20
Jul+1.8%60%20
Aug−1.6%35%20
Sep−0.5%45%20
Oct−0.8%30%20
Nov+2.1%70%20
Dec+0.8%45%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1452.6
MFI48.7
ADX20.5
Stochastic %K / %D86.4 / 81.3
Williams %R-20.0
CCI133
TSI / signal-6.9 / -11.9
Chaikin money flow0.06
ATR$1.95
Bollinger width4.7%
Volume vs 20-day avg0.96x
SupertrendDown

Moving averages and bands

level (price vs level)
SMA 20$85.19 (+1.4%)
SMA 50$87.38 (−1.1%)
SMA 200$80.67 (+7.1%)
EMA 21$85.62 (+0.9%)
EMA 50$85.99 (+0.5%)
EMA 200$81.35 (+6.2%)
Bollinger upper$87.18 (−0.9%)
Bollinger lower$83.21 (+3.8%)
Parabolic SAR$80.21 (+7.7%)
Open the live chart, 110+ indicators

About Henry Schein, Inc.

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

https://www.henryschein.com

Key executives

NameTitlePayBorn
Andrea AlbertiniChief Executive Officer of Global Distribution & Technology$1.8M1970
Mark E. MlotekExecutive Vice President & Chief Strategic Officer$1.7M1956
Michael Saul EttingerExecutive Vice President & Chief Operating Officer$1.4M1961
Ronald N. SouthSenior Vice President & Chief Financial Officer$1.2M1962
Christopher PendergastSenior Vice President & Chief Technology Officer—1963
Frederick LoweryCEO & Director—1971
Graham StanleyVice President of Investor Relations & Strategic Finance Project Officer——
Kelly MurphySenior Vice President & General Counsel—1981

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
Stanley M. Bergman Chairman and Former Chief Executive Officer (Principal Executive Officer)2025$1.7M$7.8M$2.3M$12.0M
Mark E. Mlotek Executive Vice President and Chief Strategic Officer2025$750,000$2.0M$901,039$3.7M
Michael S. Ettinger Executive Vice President and Chief Operating Officer2025$750,000$2.0M$653,355$3.4M
Andrea Albertini Chief Executive Officer, Global Distribution and Technology2025$712,500$1.6M$561,660$3.4M
Ronald N. South Senior Vice President, Chief Financial Officer (Principal Financial Officer)2025$640,000$1.5M$509,166$2.7M

Employees

18k201819k201919k202022k202122k202225k202325k202425k2025

Dividends

Ex-dateAmountPaid
None on file.

Moat model

None · Efficient Scale · 2026-06-27
Cost advantage30
Intangibles31
Switching costs12
Network effect50
Efficient scale85
Our component scores (0-100) and overall 37.0; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms